Yi Yu

8PUBLICATIONS

143CO-AUTHORS

Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targets

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (8)

Sort by Publication Date:

|Jun 10, 2026

TNG917 is a Potent and Selective Inhibitor of Histone Lysine Methyltransferases EHMT1/2 that Enhances Anti-Tumor Immunity and Immunotherapy Efficacy.

|Apr 19, 2026

TNG961 is a selective oral HBS1L molecular glue degrader for the treatment of FOCAD-deleted cancers.

|Aug 29, 2025

TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11-Mutant Tumors to Anti-PD-1 Immunotherapy.

Leanne G Ahronian, Soumyadip Sahu, Minjie Zhang

|May 06, 2025

CRISPR Screens Identify POLB as a Synthetic Lethal Enhancer of PARP Inhibition Exclusively in BRCA-Mutated Tumors.

Katherine Lazarides, Justin L Engel, Michele Meseonznik

|Feb 27, 2025

Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.

Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do

|Jan 31, 2025

Characterization of TNG348: A Selective, Allosteric USP1 Inhibitor That Synergizes with PARP Inhibitors in Tumors with Homologous Recombination Deficiency.

Antoine Simoneau, Charlotte B Pratt, Hsin-Jung Wu

Pageof 2

Frequent Collaborators

6 joint publications

Jannik N Andersen

6 joint publications

Douglas A Whittington

John P Maxwell

Alan Huang

Samuel R Meier

William D Mallender

Hongxiang Zhang

Binzhang Shen

Minjie Zhang

Madhavi Bandi

Frequent Collaborators

6 joint publications

Jannik N Andersen

6 joint publications

Douglas A Whittington

5 joint publications

John P Maxwell

5 joint publications

Alan Huang